before describing the present invention in detail , it is to be understood that this invention is not limited to particular drugs or drug delivery systems , as such may vary . it is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only , and is not intended to be limiting . it must be noted that , as used in this specification , the singular forms “ a ,” “ an ” and “ the ” include plural referents unless the context clearly dictates otherwise . thus , for example , reference to “ a pharmacologically active agent ” includes a combination of two or more pharmacologically active agents , and the like . in describing the present invention , the following terminology will be used in accordance with the definitions set out below . as used herein in the claim ( s ), when used in conjunction with the word “ comprising ”, the words “ a ” or “ an ” may mean one or more than one . as used herein “ another ” may mean at least a second or more . the terms “ active agent ,” “ drug ” and “ pharmacologically active agent ” are used interchangeably herein to refer to a chemical material or compound which , when administered to an organism ( human or animal ) induces a desired pharmacologic effect . included are derivatives and analogs of those compounds or classes of compounds specifically mentioned which also induce the desired pharmacologic effect . the term “ topical administration ” is used in its conventional sense to mean delivery of a topical drug or pharmacologically active agent to the skin or mucosa . “ carriers ” or “ vehicles ” as used herein refer to carrier materials suitable for drug administration . carriers and vehicles useful herein include any such materials known in the art , e . g ., any liquid , gel , solvent , liquid diluent , solubilizer , or the like , which is nontoxic and which does not interact with other components of the composition in a deleterious manner . by an “ effective ” amount of a drug or pharmacologically active agent is meant a nontoxic but sufficient amount of the drug or agent to provide the desired effect . the term “ capsaicin or capsaicins ” as used herein is intended to encompass not only the compound capsaicin , but also homocapsaicin , nordihydrocapsaicin , dihydrocapsaicin , homodihydrocapsaicin or any compounded mixture thereof ( see fig1 ). the present invention provides for certain novel pharmaceutical compositions containing ester derivatives of capsaicin and ester derivatives of myristoleic acid that are highly lipophilic . the ester of capsaicin and the ester of myristoleic acid set forth herein are enzymatically cleaved to the parent compound . thus , the pharmaceutical compositions set forth herein provide for a novel form of therapy of diseases amendable to treatment with capsaicin and esters of myristoleic acid . the combination of the ester derivatives of capsaicin and the ester of myristoleic acid of the present invention would have significant utility over capsaicin or myristoleic acid and existing derivatives currently described in the patent and scientific literature . in particular , in view of their high lipophilicity , non - irritation to the skin , significantly less burning sensation at the site of application and stability , these derivatives would be more bioavailable when administered topically compared to capsaicin or myristoleic acid . in addition , because of their stability and non - toxic nature , these agents can be made more readily available to the general public . the inventors have surprisingly and unexpectedly discovered that the ester derivatives of capsaicin in combination with the esters of myristoleic acid have therapeutic utility in treating pain in humans . these compositions thus provide for a novel form of therapy of any disease or condition wherein capsaicin or myristoleic acid is believed to be of benefit , including but not limited to , post - herpetic neuralgia , shingles ( herpes zoster ), diabetic neuropathy , postmastectomy pain syndrome , oral neuropathic pain , trigeminal neuralgia , temperomandibular joint disorders , pruritus , cluster headache , osteoarthritis , arthritis pain , rhinopathy , oral mucositis , cutaneous allergy , detrusor hyperreflexia , loin pain / hematuria syndrome , neck pain , amputation stump pain , reflex sympathetic dystrophy and pain due to skin tumor . the present invention generally pertains to pharmaceutical compositions containing a compound of formula ( ia ): wherein cap refers to collectively the capsaicins represented in fig1 and a compound of formula ( ib ): wherein mco refers to myristoleic acid represented in fig3 . in formula ia and ib , r is selected from alkyl groups of up to about 18 carbon atoms and aryl groups of up to about 18 carbon atoms and alkylene group of up to about 18 carbon atoms and an arylene group of up to about 18 carbon atoms . the alkyl , aryl and alkylene groups may be substituted or unsubstituted , branched or straight chains . in addition , r may contain heteroatoms and may be straight chained or branched . examples of suitable straight - chain alkyl groups in formula ia and ib include methyl , ethyl , propyl , butyl , hexyl , heptyl , octyl , dodecyl , 1 - pentadecyl , 1 - heptadecyl 1 - hexadecyl , 1 - octadecyl and the like groups . examples of suitable branched chain alkyl groups in formula i include isopropyl , sec - butyl , t - butyl , 2 - methylbutyl , 2 - pentyl , 3 - pentyl and the like groups . examples of suitable cyclic alkyl groups in formula ia and ib include cyclopropyl , cyclobutyl , cyclopentyl and cyclohexyl groups . examples of suitable “ alkenyl ” groups in ia and ib include vinyl ( ethenyl ), 1 - propenyl , i - butenyl , pentenyl , hexenyl , n - decenyl and c - pentenyl and the like . the groups may be substituted , generally with 1 or 2 substituents , wherein the substituents are independently selected from halo , hydroxy , alkoxy , amino , mono - and dialkylamino , nitro , carboxyl , alkoxycarbonyl , and cyano groups . by the expression “ phenalkyl groups wherein the alkyl moiety contains 1 to 3 or more carbon atoms ” is meant benzyl , phenethyl and phenylpropyl groups wherein the phenyl moiety may be substituted . when substituted , the phenyl moiety of the phenalkyl group may contain independently from 1 to 3 or more alkyl , hydroxy , alkoxy , halo , amino , mono - and dialkylamino , nitro , carboxyl , alkoxycarbonyl and cyano groups . examples of suitable “ heteroaryl ” in formula ia and ib are pyridinyl , thienyl or imidazolyl . as noted herein , the expression “ halo ” is meant in the conventional sense to include f , cl , br , and i . among the compounds represented by the general formula ia and ib , preferred compounds are such in which r is one of the following groups : methyl , ethyl , propyl , butyl , pentyl , hexyl , 1 - pentadecyl , 1 - heptadecyl , 1 - hexadecyl , 1 - octadecyl , isobutyl , methoxyethyl , ethoxyethyl , benzyl and nicotinyl . the compounds of formula ia are esters of capsacin and its analogues and compounds of ib are esters of myristoleic acid . however , information in the literature do not disclose or indicate the esters of capsaicin have any utility as prodrug forms in combination with the esters of myristoleic acid suitable for oral and topical delivery for treating diseases such as post - herpetic neuralgia , shingles ( herpes zoster ), diabetic neuropathy , postmastectomy pain syndrome , oral neuropathic pain , trigeminal neuralgia , temperomandibular joint disorders , pruritus , cluster headache , osteoarthritis , arthritis pain , rhinopathy , oral mucositis , cutaneous allergy , detrusor hyperreflexia , loin pain / hematuria syndrome , neck pain , amputation stump pain , reflex sympathetic dystrophy and pain due to skin tumor . the compounds used in the present invention can be prepared by any method known to those of ordinary skill in the art . for example , the esters of myrisoleic acid can be obtained commercially as oil , powder or wax ( ehp products inc , usa ). various methods have been described in the literature pertaining to the synthesis of a number of esters of carboxylic acids and phenols ( march &# 39 ; s advanced organic chemistry : reactions , mechanisms , and structure , 5th edition , by michael b . smith and jerry march , john wiley and sons , inc , 2001 ). one method that has been utilized for efficient preparation of the ester of capsaicin of the present invention is through dissolution of the compound in methylene dichloride . since capsaicin usp27 conatins & gt ; 95 % of capsaicins , to this solution slightly in excess of 1 . 1 mole equivalent of anhydrous triethylamine is added with stirring at room temperature . to this solution slightly in excess of 1 mole equivalent of an acid chloride is added with stirring while keeping the temperature around 25 ° c . after that , the solution was refluxed for 2 - 5 hours and stirred for 12 - 17 hours at room temperature . the reaction mixture was then washed with equal amount of water three to four times to remove the unreacted amine and its salt in a separating funnel . the organic phase was washed 3 - 4 times with dilute hydrochloric acid solution in a separating funnel to remove any amine present in the organic solution . the reaction mixture was then washed with equal amount of 10 % sodium carbonate solution three to four times to remove the unreacted acid and salts in a separating funnel . the reaction mixture was then washed with equal amount of water three to four times in a separating funnel . the organic phase was dried with anhydrous sodium sulfate overnight and the methylene dichloride was removed in a rotary evaporator under vacuum . the resultant oily or waxy material is called the ester capsaicin as all of the phenols present capsaicin is converted into the corresponding ester . certain embodiments of the present invention pertain to pharmaceutical compositions comprising the esters of capsaicins and esters of myristoleic acid set forth herein . the phrases “ pharmaceutical ,” “ pharmaceutically ,” or “ pharmacologically acceptable ” refer to molecular entities and compositions that do not produce an unacceptably adverse , allergic or other untoward reaction when administered to an animal , or human , as appropriate . as used herein , “ pharmaceutical ” includes any and all solvents , dispersion media , coatings , antibacterial and antifungal agents , isotonic and absorption delaying agents and the like . the use of such media and agents for pharmaceutical active substances is well known in the art . except insofar as any conventional media or agent is incompatible with the active ingredients , its use in the therapeutic compositions is contemplated . supplementary active ingredients to treat the disease of interest , such as other anti - cancer agents or anti - inflammatory agents , can also be incorporated into the compositions . pharmaceutical compositions of the present invention will include an effective amount of one or more of the ester derivatives of capsaicin and the ester derivatives of myristoleic acid set forth herein that are clinically determined to be useful in the treatment of the particular disease under consideration . one of ordinary skill in the art would be familiar with what type of dosage is required for treatment of the particular pathological condition that is present in the subject . no undue experimentation would be involved . when used for therapy , the compositions of the present invention are administered to subjects in therapeutically effective amounts . for example , an effective amount of the ester of capsaicin in a patient with diabetic neuropathy may be an amount that promotes the healing of the pain associated with the neuropathy . the dose will depend on the nature of the disease , the subject , the subject &# 39 ; s history , and other factors . preparation of such compositions is discussed in other parts of this specification . as discussed above , the derivatives of capsaicin set forth herein have greater lipophilicity and significantly less irritation to the skin than capsaicin . one advantage of these esters is that they can be incorporated into a cream or ointment form at a higher percentage by weight as compared to capsaicin . another advantage is that these compositions have a very low toxicity and irritation to the skin as compared to formulations of capsaicin . the compositions of the capsaicin derivatives and myristoleic acid derivatives of the present invention can be delivered by any method known to those of ordinary skill in the art . for example , the pharmaceutical compositions can be delivered by topical or oral delivery routes . compositions employing the esters of capsaicin and esters of myristoleic acid set forth herein will contain a biologically effective amount of the derivative . as used herein a biologically effective amount of a compound or composition refers to an amount effective to alter , modulate or reduce disease conditions . one of ordinary skill in the art would be familiar with methods of determining a biologically effective amount of a therapeutic agent . for example , a biologically effective amount may be about 0 . 1 mg / kg to about 50 mg / kg or greater the therapeutic combination of esters of capsaicin and esters of myristoleic acid of the present invention may be administered alone or in combination with one or more additional therapeutic esters of the present invention . in other embodiments , the therapeutic combination of ester of capsaicin and ester of myristoleic acid is administered in combination with one or more secondary forms of therapy directed to the disease or condition to be treated . these are discussed in greater detail below . additional pharmaceutical compounds may be administered in the same pharmaceutical composition , or in a separate dosage form , such as in a separate oral , intramuscular , or intravenous dosage forms taken at the same time . the therapeutic agents of the present invention may be supplied in any form known to those of ordinary skill in the art . for example , the therapeutic agent may be supplied as a liquid or as a solution . the pharmaceutical compositions may contain a preservative to prevent the growth of microorganisms . it must be chemically and physically stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms , such as bacteria and fungi . the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents , for example , parabens , chlorobutanol , phenol , sorbic acid , thimerosal , and the like . the formulations according to the invention having been described herein may influence the ordinarily skilled artesian to make similar formulations using components that will be known in the art , without departing from the invention which is claimed herein . the pharmaceutical formulations of the esters of capsaicin and esters of myristoleic acid according to the present invention offer several advantages over the existing formulations . they can be topically applied and relatively high concentrations of the esters of capsaicin can be loaded into patients with high bioavailability . thus the frequency of dosage can be reduced . thus within the spirit , the invention is related to improved formulations and methods of using the same when administering such formulations to patients . as mentioned herein above a number of excipients may be appropriate for use in the formulation which comprises the composition according to the present invention . the inclusion of excipients and the optimization of their concentration for their characteristics such as for example ease of handling or carrier agents will be understood by those ordinarily skilled in the art not to depart from the spirit of the invention as described herein and claimed herein below . following preparation of the pharmaceutical compositions of the present invention , it may be desirable to quantify the amount of the esters of capsaicin and esters of myristoleic acid in the pharmaceutical composition . methods of measuring concentration of a drug in a composition include numerous techniques that are well - known to those of skill in the art . selected examples include chromatographic techniques . there are many kinds of chromatography which may be used in the present invention : drug - specific assays , adsorption , partition , ion - exchange and molecular sieve , and many specialized techniques for using them including column , paper , thin - layer chromatography , gas chromatography , and high performance liquid chromatography ( hplc ). one of ordinary skill in the art would be familiar with these and other related techniques . certain topical formulations of the present invention may contain moisturizing agents . non - limiting examples of moisturizing agents that can be used with the compositions of the present invention include amino acids , chondroitin sulfate , diglycerin , erythritol , fructose , glucose , glycerin , glycerol polymers , glycol , 1 , 2 , 6 - hexanetriol , honey , hyaluronic acid , hydrogenated honey , hydrogenated starch hydrolysate , inositol , lactitol , maltitol , maltose , mannitol , natural moisturization factor , peg - 15 butanediol , polyglyceryl sorbitol , salts of pyrollidone carboxylic acid , potassium pca , propylene glycol , sodium glucuronate , sodium pca , sorbitol , sucrose , trehalose , urea , and xylitol . other examples include acetylated lanolin , acetylated lanolin alcohol , acrylates / c10 - 30 alkyl acrylate crosspolymer , acrylates copolymer , alanine , algae extract , aloe barbadensis , aloe - barbadensis extract , aloe barbadensis gel , althea officinalis extract , aluminum starch octenylsuccinate , aluminum stearate , apricot ( prunus armeniaca ) kernel oil , arginine , arginine aspartate , arnica montana extract , ascorbic acid , ascorbyl palmitate , aspartic acid , avocado ( persea gratissima ) oil , barium sulfate , barrier sphingolipids , butyl alcohol , beeswax , behenyl alcohol , beta - sitosterol , bht , birch ( betula alba ) bark extract , borage ( borago officinalis ) extract , 2 - bromo - 2 - nitropropane - 1 , 3 - diol , butcherbroom ( ruscus aculeatus ) extract , butylene glycol , calendula officinalis extract , calendula officinalis oil , candelilla ( euphorbia cerifera ) wax , canola oil , caprylic / capric triglyceride , cardamon ( elettaria cardamomum ) oil , carnauba ( copernicia cerifera ) wax , carrageenan ( chondrus crispus ), carrot ( daucus carota sativa ) oil , castor ( ricinus communis ) oil , ceramides , ceresin , ceteareth - 5 , ceteareth - 12 , ceteareth - 20 , cetearyl octanoate , ceteth - 20 , ceteth - 24 , cetyl acetate , cetyl octanoate , cetyl palmitate , chamomile ( anthemis nobilis ) oil , cholesterol , cholesterol esters , cholesteryl hydroxystearate , citric acid , clary ( salvia sclarea ) oil , cocoa ( theobroma cacao ) butter , coco - caprylate / caprate , coconut ( cocos nucifera ) oil , collagen , collagen amino acids , corn ( zea mays ) oil , fatty acids , decyl oleate , dextrin , diazolidinyl urea , dimethicone copolyol , dimethiconol , dioctyl adipate , dioctyl succinate , dipentaerythrityl hexacaprylate / hexacaprate , dmdm hydantoin , dna , erythritol , ethoxydiglycol , ethyl linoleate , eucalyptus globulus oil , evening primrose ( oenothera biennis ) oil , fatty acids , tructose , gelatin , geranium maculatum oil , glucosamine , glucose glutamate , glutamic acid , glycereth - 26 , glycerin , glycerol , glyceryl distearate , glyceryl hydroxystearate , glyceryl laurate , glyceryl linoleate , glyceryl myristate , glyceryl oleate , glyceryl stearate , glyceryl stearate se , glycine , glycol stearate , glycol stearate se , glycosaminoglycans , grape ( vitis vinifera ) seed oil , hazel ( corylus americana ) nut oil , hazel ( corylus avellana ) nut oil , hexylene glycol , honey , hyaluronic acid , hybrid safflower ( carthamus tinctorius ) oil , hydrogenated castor oil , hydrogenated coco - glycerides , hydrogenated coconut oil , hydrogenated lanolin , hydrogenated lecithin , hydrogenated palm glyceride , hydrogenated palm kernel oil , hydrogenated soybean oil , hydrogenated tallow glyceride , hydrogenated vegetable oil , hydrolyzed collagen , hydrolyzed elastin , hydrolyzed glycosaminoglycans , hydrolyzed keratin , hydrolyzed soy protein , hydroxylated lanolin , hydroxyproline , imidazolidinyl urea , iodopropynyl butylcarbamate , isocetyl stearate , isocetyl stearoyl stearate , isodecyl oleate , isopropyl isostearate , isopropyl lanolate , isopropyl myristate , isopropyl palmitate , isopropyl stearate , isostearamide dea , isostearic acid , isostearyl lactate , isostearyl neopentanoate , jasmine ( jasminum officinale ) oil , jojoba ( buxus chinensis ) oil , kelp , kukui ( aleurites moluccana ) nut oil , lactamide mea , laneth - 16 , laneth - 10 acetate , lanolin , lanolin acid , lanolin alcohol , lanolin oil , lanolin wax , lavender ( lavandula angustifolia ) oil , lecithin , lemon ( citrus medica limonum ) oil , linoleic acid , linolenic acid , macadamia ternifolia nut oil , magnesium stearate , magnesium sulfate , maltitol , matricaria ( chamomilla recutita ) oil , methyl glucose sesquistearate , methylsilanol pca , microcrystalline wax , mineral oil , mink oil , mortierella oil , myristyl lactate , myristyl myristate , myristyl propionate , neopentyl glycol dicaprylate / dicaprate , octyldodecanol , octyldodecyl myristate , octyldodecyl stearoyl stearate , octyl hydroxystearate , octyl palmitate , octyl salicylate , octyl stearate , oleic acid , olive ( olea europaea ) oil , orange ( citrus aurantium dulcis ) oil , palm ( elaeis guineensis ) oil , palmitic acid , pantethine , panthenol , panthenyl ethyl ether , paraffin , pca , peach ( prunus persica ) kernel oil , peanut ( arachis hypogaea ) oil , peg - 8 c12 - 18 ester , peg - 15 cocamine , peg - 150 distearate , peg - 60 glyceryl isostearate , peg - 5 glyceryl stearate , peg - 30 glyceryl stearate , peg - 7 hydrogenated castor oil , peg - 40 hydrogenated castor oil , peg - 60 hydrogenated castor oil , peg - 20 methyl glucose sesquistearate , peg40 sorbitan peroleate , peg - 5 soy sterol , peg - 10 soy sterol , peg - 2 stearate , peg - 8 stearate , peg - 20 stearate , peg - 32 stearate , peg40 stearate , peg - 50 stearate , peg - 100 stearate , peg - 150 stearate , pentadecalactone , peppermint ( mentha piperita ) oil , petrolatum , phospholipids , polyamino sugar condensate , polyglyceryl - 3 diisostearate , polyquaternium - 24 , polysorbate 20 , polysorbate 40 , polysorbate 60 , polysorbate 80 , polysorbate 85 , potassium myristate , potassium palmitate , potassium sorbate , potassium stearate , propylene glycol , propylene glycol dicaprylate / dicaprate , propylene glycol dioctanoate , propylene glycol dipelargonate , propylene glycol laurate , propylene glycol stearate , propylene glycol stearate se , pvp , pyridoxine dipalmitate , quaternium - 15 , quaternium - 18 hectorite , quaternium - 22 , retinol , retinyl palmitate , rice ( oryza sativa ) bran oil , rna , rosemary ( rosmarinus officinalis ) oil , rose oil , safflower ( carthamus tinctorius ) oil , sage ( salvia officinalis ) oil , salicylic acid , sandalwood ( santalum album ) oil , serine , serum protein , sesame ( sesamum indicum ) oil , shea butter ( butyrospermum parkii ), silk powder , sodium chondroitin sulfate , sodium dna , sodium hyaluronate , sodium lactate , sodium palmitate , sodium pca , sodium polyglutamate , sodium stearate , soluble collagen , sorbic acid , sorbitan laurate , sorbitan oleate , sorbitan palmitate , sorbitan sesquioleate , sorbitan stearate , sorbitol , soybean ( glycine soja ) oil , sphingolipids , squalane , squalene , stearamide mea - stearate , stearic acid , stearoxy dimethicone , stearoxytrimethylsilane , stearyl alcohol , stearyl glycyrrhetinate , stearyl heptanoate , stearyl stearate , sunflower ( helianthus annuus ) seed oil , sweet almond ( prunus amygdalus dulcis ) oil , synthetic beeswax , tocopherol , tocopheryl acetate , tocopheryl linoleate , tribehenin , tridecyl neopentanoate , tridecyl stearate , triethanolamine , tristearin , urea , vegetable oil , water , waxes , wheat ( triticum vulgare ) germ oil , and ylang ylang ( cananga odorata ) oil . certain topical formulations of the present invention may also contain one or more antioxidants . non - limiting examples of antioxidants that can be used with the compositions of the present invention include acetyl cysteine , ascorbic acid , ascorbic acid polypeptide , ascorbyl dipalmitate , ascorbyl methylsilanol pectinate , ascorbyl palmitate , ascorbyl stearate , bha , bht , t - butyl hydroquinone , cysteine , cysteine hcl , diamylhydroquinone , di - t - butylhydroquinone , dicetyl thiodipropionate , dioleyl tocopheryl methylsilanol , disodium ascorbyl sulfate , distearyl thiodipropionate , ditridecyl thiodipropionate , dodecyl gallate , erythorbic acid , esters of ascorbic acid , ethyl ferulate , ferulic acid , gallic acid esters , hydroquinone , isooctyl thioglycolate , kojic acid , magnesium ascorbate , magnesium ascorbyl phosphate , methylsilanol ascorbate , natural botanical anti - oxidants such as green tea or grape seed extracts , nordihydroguaiaretic acid , octyl gallate , phenylthioglycolic acid , potassium ascorbyl tocopheryl phosphate , potassium sulfite , propyl gallate , quinones , rosmarinic acid , sodium ascorbate , sodium bisulfite , sodium erythorbate , sodium metabisulfite , sodium sulfite , superoxide dismutase , sodium thioglycolate , sorbityl furfural , thiodiglycol , thiodiglycolamide , thiodiglycolic acid , thioglycolic acid , thiolactic acid , thiosalicylic acid , tocophereth - 5 , tocophereth - 10 , tocophereth - 12 , tocophereth - 18 , tocophereth - 50 , tocopherol , tocophersolan , tocopheryl acetate , tocopheryl linoleate , tocopheryl nicotinate , tocopheryl succinate , and tris ( nonylphenyl ) phosphite . as noted in other parts of this specification , there is substantial evidence that capsaicin would be beneficial in the treatment of a wide variety of pathological conditions . the term “ treat ” or “ treatment ” means that the symptoms associated with one or more conditions mentioned above are alleviated or reduced in severity or frequency and the term “ prevent ” means that subsequent occurrences of such symptoms are avoided or that the frequency between such occurrences is prolonged . conditions amenable to treatment or prevention with capsaicin are specifically detailed for post - herpetic neuralgia ( bernstein et al ., 1989 ; watson et al ., 1993 ), diabetic neuropathy ( capsaicin study group , 1992 ), postmastectomy pain syndrome ( watson and evans 1992 ; dini et al ., 1993 ), oral neuropathic pain , trigeminal neuralgia , and temperomandibular joint disorders ( epstein and marcoe , 1994 ; hersh et al ., 1994 ), cluster headache ( following intranasal application ; marks et al ., 1993 ), osteoarthritis ( mccarthy and mccarthy , 1992 ), and dermatological and cutaneous conditions ( hautkappe et al ., 1998 ). examples of pathological conditions responsive to capsaicin therapy include , but are not limited to , post - herpetic neuralgia , shingles ( herpes zoster ), diabetic neuropathy , postmastectomy pain syndrome , oral neuropathic pain , trigeminal neuralgia , temperomandibular joint disorders , pruritus , cluster headache , osteoarthritis , arthritis pain , rhinopathy , oral mucositis , cutaneous allergy , detrusor hyperreflexia , loin pain / hematuria syndrome , neck pain , amputation stump pain , reflex sympathetic dystrophy and pain due to skin tumor . examples of pathological conditions responsive to esters of myristoleic acid include , but are not limited to , arthritis pain , osteoarthritis and inflammation . it is expected that the novel pharmaceutical composition containing ester derivatives of capsaicin and ester derivatives of myristoleic acid set forth herein would be beneficial in the treatment and prevention of any of the diseases set forth above . one of ordinary skill in the art would be familiar with the many diseases and conditions that would be amenable to treatment with one or more of the ester derivatives of capsaicin set forth herein . some embodiments of the claimed methods of the present invention involve administering to the subject a secondary form of therapy in addition to one or more of the therapeutic combination of ester derivatives of capsaicin and ester derivatives of myristoleic acid set forth herein . for example , if the disease is a hyperproliferative disease , such as cancer , the secondary therapy may be a chemotherapeutic agent , radiation therapy , surgical therapy , immunotherapy , gene therapy , or other form of anticancer therapy well - known to those of ordinary skill in the art . if the disease is an inflammatory disease such as arthritis , exemplary secondary forms of therapy include non - steroidal anti - inflammatory agents , steroids and immunosuppressant therapy . in order to increase the effectiveness of the therapeutic agent disclosed herein , it may be desirable to combine the therapeutic agent of the present invention with the secondary therapeutic agent . these compositions would be provided in a combined amount effective to provide for a therapeutic response in a subject . one of ordinary skill in the art would be able to determine whether the subject demonstrated a therapeutic response . this process may involve administering the therapeutic agent of the present invention and the secondary therapeutic agent to the subject at the same time . this may be achieved by administering a single composition or pharmacological formulation that includes both agents , or by administering two distinct compositions or formulations , at the same time , wherein one composition includes the ester derivative of capsaicin and ester derivative of myristoleic acid of the present invention and the other includes the secondary agent . alternatively , the therapeutic agent of the present invention may precede or follow the treatment with the secondary agent by intervals ranging from minutes to weeks . in embodiments where the secondary agent and the ester derivatives of the present invention are separately administered , one would generally ensure that a significant period of time did not expire between the time of each delivery , such that the secondary agent and the therapeutic agent of the present invention would still be able to exert a beneficial effect on the subject . in such instances , it is contemplated that one may administer both modalities within about 24 - 48 h of each other and , more preferably , within about 12 - 24 h of each other , and even more preferably within about 30 minute - 6 h of each other . in some situations , it may be desirable to extend the time period for treatment significantly , however , where several d ( 2 , 3 , 4 , 5 , 6 or 7 ) to several wk ( 1 , 2 , 3 , 4 , 5 , 6 , 7 or 8 ) lapse between the respective administrations . various combinations may be employed , the therapeutic agent of the present invention is “ a ” and the secondary agent , such as chemotherapy , is “ b ”: administration of the compositions of the present invention to a patient will follow general protocols for the administration of therapeutic agents , such as chemotherapy where the disease to be treated is cancer . it is expected that the treatment cycles would be repeated as necessary . the following examples are included to demonstrate preferred embodiments of the invention . it should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention , and thus can be considered to constitute preferred modes for its practice . however , those of skill in the art should , in light of the present disclosure , appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention . preparation of butyryl ester of capsaicin usp27 ( formula i , r ═ c 3 h 7 ) a mixture of 30 . 5 gm (˜ 0 . 1m ) of capsaicin usp27 ( hubei xiangxi chemical industry co ., ltd , china ), 16 . 7 ml ( 0 . 12m ) of anhydrous triethylamine ( spectrum chemicals ) and 200 ml of anhydrous dichloromethane was placed into a 1000 ml 2 - neck round bottomed flask . the content was covered with aluminum foil to protect it from light exposure . the flask was fitted with a condenser fitted with a moisture trap on the top and a dropwise addition funnel . the flask was kept at room temperature and 12 . 8 ml ( 0 . 12m ) of butyryl chloride was added from the funnel into the mixture slowly with stirring . after the addition , the mixture was refluxed for 3 - 6 hours and stirred for 10 - 45 hours at room temperature . the mixture was transferred into a separating funnel and washed successively with 2 × 500 ml of water , 2 × 500 ml of dilute hydrochloric acid , 2 × 500 ml of 10 % sodium bicarbonate solution and 3 × 500 ml of type water . the organic layer was separated , dried with anhydrous magnesium sulfate and the dichloromethane was removed under vacuum to produce a clear , yellow viscous oil ( 95 % of theoretical ). preparation of hexanoyl ester of capsaicn usp27 ( formula i , r ═ ch 3 —( ch 2 ) 4 ) the compound was prepared essentially as described in example 1 , using n - hexanoyl chloride instead of butyryl chloride . the product was recovered as a low melting viscous yellow oil . preparation of palmitoyl ester of capsaicn usp27 ( formula i , r ═ ch 3 —( ch 2 ) 14 ) the compound was prepared essentially as described in example 1 , using n - palmitoyl chloride instead of butyryl chloride . the product was recovered as a waxy yellow solid . preparation of a topical gel containing butyryl ester of capsaicin usp27 and cetyl myristoleate three compositions of capsaicin butyrate , shown in table 1 , each with a batch size of 500 gm of the gel , were prepared according to the following procedure . three compositions of capsaicin palmitate , shown in table 2 , each with a batch size of 500 gm of the gel , were prepared according to the following procedure . table 3 the composition for the preparation of capsules . ingredient amount i amount ii palmitoyl - capsaicin usp27 5 . 40 parts 10 . 8 parts microcrystalline cellulose 19 . 60 parts 14 . 20 parts cetyl myristoleate powder 350 . 00 parts 350 . 00 parts ( 20 % in corn starch ) ascorbyl palmitate 20 . 00 parts 20 . 00 parts silicon dioxide 2 . 50 parts 2 . 50 parts sodium lauryl sulfate 2 . 50 parts 2 . 50 parts total 400 . 00 parts 400 . 00 parts preparation i : the palmitoyl - capsaicin usp27 ( table 3 ; amount i ) is intensively milled with ten times its weight of cetyl myristoleate powder , the milled mixture is admixed with the remaining amount of the cetyl myristoleate powder , microcrystalline cellulose , ascorbyl palmitate sodium lauryl sulfate and silicon dioxide . the mixed powder is again milled and the composition is filled into 500 mg capsule in a conventional capsule loading machine . each capsule contains 5 . 40 mg of palmitoyl - capsaicin usp27 ( approximately 50 , 000 shu equivalent in each capsule ) and 70 mg of cetyl myristoleate and is an oral dosage unit composition with effective therapeutic action . preparation ii : the palmitoyl - capsaicin - usp27 ( table 3 ; amount ii ) is intensively milled with five times its weight of cetyl myristoleate powder , the milled mixture is admixed with the remaining amount of the cetyl myristoleate powder , microcrystalline cellulose , ascorbyl palmitate , sodium lauryl sulfate and silicon dioxide . the mixed powder is again milled and the composition is filled into 500 mg capsule in a conventional capsule loading machine . each capsule contains 10 . 8 mg of palmitoyl - capsaicin usp27 ( approximately 100 , 000 shu equivalent in each capsule ) and 70 mg of cetyl . myristoleate and is an oral dosage unit composition with effective therapeutic action . a 0 . 5 % of butyryl - capsaicin usp27 and 4 % cetyl myristoleate gel as described in example 4 was applied to the forearm of 10 healthy individuals twice daily for a two - week period in an outpatient clinic . no patients complained of burning , irritation , scaling or redness after the cream . patients returned to the clinic after having used the gel for two weeks for a visual inspection of the forearm area . the examining physician noted no redness , irritation or scaling in the area where the solution had been applied . treatment of pain with the topical formulation of butyryl capsaicin usp27 and cetyl myristoleate a 53 year old hispanic male has developed type 2 diabetes a year ago and has diabetic neuropathy in the feet . he was given the 0 . 5 % butyryl - capsaicin usp27 and 4 % cetyl myristoleate gel and the following is his testimony on the effectiveness of the oil for the treatment of cold sores . “ i was diagnosed with type 2 diabetes last year . i also have neuropathy in my feet . i had an ulcer on my foot and was treated by a local pediatric doctor in san antonio . my ulcer has since been cleared up . i control my diabetic ailment with a low - carb diet only , with no medication . i have also lost 40 lbs . since my diagnosis last year . i however feel pain on the bottom of my feet at times . since taking the cream by application on my feet , i have noticed much less discomfort than usual . the comfort that i noticed has lasted up to 24 hrs per - application . this cream really helps my condition and would like to let your research company to know about your product ”. a 45 year old white male developed constant pain in the finger due to dislocation and has to be injected cortisone every 3 months to alleviate the pain . he was given 1 % butyryl capsaicin usp27 and 4 % cetyl myristoleate gel for topical application . he gave the following testimony about the treatment . “ every 3 months or so , i have a cortisone shot in a finger i dislocated a few years ago . i used the 1 % gel given to me . it did a very good job for the pain and making movement a lot easier . the swelling was reduced as well as the pain . i did however , find that the product does have a tendency to get a little warm . that &# 39 ; s a good thing , other than it still transfers after hand washing , and you might get a little warm where you don &# 39 ; t need it . i feel like this product would be beneficial for people who can not or who would rather not take oral pain medication ” a 40 year old white female developed diabetic neuropathy in 2000 and was given 0 . 5 % butyryl capsaicin and 4 % cetyl myristoleate gel for treating her pain in the feet . she gave the following testimony about the treatment . “ i was diagnosed with neuropathy in 2000 . there never has been much they could do for me other than give me pain medication that &# 39 ; s addictive . at this time , i &# 39 ; m on neurontin 1800 mg a day , vicodin 5 . 6 tablets a day . diclofenac 150 mg a day , and also get injections in my feet . in the last 7 months i have had 5 different cast on my left foot . since my left foot has a cast my right foot has become worse because all of my weight has been on my right foot . i used the crème and within 30 min . i could feel the difference . later i was up walking and realized there was no pain at all . at night i don &# 39 ; t sleep well because of the pain , but i was able to go to sleep the whole night through without cramps and pain . my cast will be coming off in 8 days and i can &# 39 ; t wait to try it on my left foot ”. a 65 year old white female developed pain due to pinched nerve and was treated with the 0 . 5 % butyryl capsaicin usp27 and 4 % cetyl myristoleate gel . she gave the following testimony about the treatment . “ over a period of years , periodically a pinched nerve would occur in the left lower side of my back . this required chiropractic treatment which at times was not always successful requiring several additional treatments . after using the cream , my pain has disappeared and that was three days ago and still no pain ”. a 49 year old white male developed diabetic neuropathy in 2001 and was given 0 . 5 % butyryl capsaicin usp27 and 4 % cetyl myristoleate gel for treating his pain in the feet . he gave the following testimony about the treatment . “ i have diabetic neuropathy brought on by extreme intra - venous application of antibiotics for a six day period . since that time i have experienced unmanageable pain causing sleep depravation , anxiety with no relief on the market . prescriptions for antidepressants were given by my personal physician but to no avail now with this cream i can sleep without any disturbances . nothing on the market today could help me without the use of addicting narcotics that were marginally effective at best ”. a 62 year old white female developed neuropathy in 1975 and was given 0 . 5 % butyryl capsaicin usp27 and 4 % cetyl myristoleate gel for treating her pain in the feet . she gave the following testimony about the treatment . “ my neuropathy numbness in feet and hands first started after back surgery in 1975 my l4 and 5 were fused and some disks removed . the numbness and pain increased after surgery for a double mastectomy which was botched by a doctor inexperienced at this surgery in 1988 causing sever pain in my abdominal muscles and up my chest . in 1992 i was in the hospital for depression a new doctor prescribed percocet medication for my pain . the percocet helped but i had to take 8 a day 5 / 325 mgs with anti depression medication at the time . the pain was so overwhelming after 4 years that i decided one day to end it all and i was found by my husband on the floor . i had kept my pain a secret over the 4 years hoping it would just eventually go away and i had never told my family that i was suffering so much . i had overdosed with the percocet in an attempt to end my pain for good . i recovered some and i tried to cut back on the percocet and got down to 1 a day to prevent addiction . the increase in pain and numbness was causing me to stumble when i walked . a neurologist in 1998 suggested that i try neurontin which is used for epilepsy . i think i was taking 100 mgs 3 times a day at first then increased in 6 weeks to 200 mgs 3 times a day , when that failed we went up to 300 mgs 3 times a day . the 300 mgs was starting to help some but they had to increase to 800 mgs 5 times a day to really help my pain . this helped more than the percocet alone but i still needed to keep the percocet at reduced amounts . i fell and broke my back fusion in 2000 . new back surgery attempted to fuse my back again but in 2003 doctors had to use rods and pins to secure it . with each surgery my numbness and pain would increase . i tried water therapy and various physical therapies but nothing could relieve my pain . i have had other injuries as well , in 2002 a broken right ankle and compression fracture in my right knee and in 2003 i broke my left ankle . in october 2005 a doctor specializing in neurological disorders said the neurontin was probably weakening my bones and switched me to a generic version of the same medication and dropped the dose to 50 mgs a day . my pain increased immediately and i went through withdrawals with the smaller dose . this doctor said if the pain didn &# 39 ; t decrease i was to increase one tablet more a day each week till the end of the 4 th week and return to him . i never went back to this doctor and just increased back to 800 mgs 5 times a day to cope with the pain , burning , and itching feelings . i had to take depression medication again at this time . i tried a new topical cream just this week jul . 11 , 2006 being developed in san antonio , tex . one of my most disruptive symptoms in my feet would cause me to involuntarily jump in bed and i was beginning to feel this come on when i applied the cream to my left foot . the symptoms just stopped ! usually this symptom would last several hours to even days . i have burning sensations in both hands and up my forearm but after applying this cream i had my first relief from that burning feeling since my back surgeries in 2003 ! this cream has done more to relieve my symptoms than both percocet and neurontin has ever done for me ! i now have renewed hope to stop taking all this internal medication that is bound to hurt my liver and is weakening my bones ”.
the present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid . these derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis . these derivatives have a higher lipophilicity , lipid solubility and less irritation to the skin than the parent compound , and hence are better able to be incorporated into certain pharmaceutical formulations , including cream and ointment pharmaceutical formulations . the pharmaceutical compositions are useful for pain management in mammals in vivo and have been contemplated to be used in the treatment of various pains in humans .